Avanos divests Hyaluronic Acid product line to Channel-Markers Medical

Avanos (AVNS) Medical announced the divestiture of its Hyaluronic Acid product line to Channel-Markers Medical, a privately held company based in Raleigh, NC. The divested portfolio includes the TriVisc and GenVisc 850 injection products, which are indicated for the treatment of osteoarthritis pain in the knee. These injectable HA therapies are designed to help patients manage OA symptoms and improve joint function. With this announcement, ownership of Avanos’ HA product line has officially transferred to CMM. Avanos will provide transition support through the end of 2025 to ensure uninterrupted service and support for customers, partners, and patients.